Dissecting the Protective Effect of CD8+ T Cells in Response to SARS-CoV-2 mRNA Vaccination and the Potential Link with Lymph Node CD8+ T Cells
CD8+ T cells in response to SARS-CoV-2 mRNA vaccine and SARS-CoV-2 infection. (a) Response to mRNA vaccine: The SARS-CoV-2 mRNA vaccine consists of an LNP-encapsulated mRNA strand that encodes the SARS-CoV-2 Spike glycoprotein, which elicits systemic immune responses upon injection. The vaccine-elicited immune response begins with the endocytosis of the LNP and release and processing of the mRNA intracellularly, which is then processed into small peptide fragments. The peptide fragments act as an endogenous antigen and are presented via the MHC class I molecule. The peptide-MHC I complexes are recognized by the TCRs of the CD8+ T cells. CD8+ T cells become activated upon the recognition of antigen, followed by differentiation into spike-specific memory CD8+ T cells. (b) Two response pathways to infection: (i) Perforin-mediated pathway: Memory CD8+ T cells recognize the infected cell and release effector molecules, such as PFN, GzmB, IFN-γ and TNF. PFN forms pores on the plasma membrane of the target cell, allowing GzmB to enter the cytosol leading to cell apoptosis via signalling cascades. (ii) Fas-mediated pathway: Apoptosis of target cells can also be initiated via the interaction of the Fas receptor on its surface and FasL on CD8+ T cells. FasL, Fas ligand; GzmB, granzyme B; IFN-γ, Interferon-gamma; LNP, lipid nanoparticle; mRNA, messenger RNA; MHC I, major histocompatibility complex class I molecule; PFN, perforin; TCR, T cell receptor; TNF, Tumor necrosis factor. Figure was created with BioRender.